Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2018-03-26 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Opthea Doses wAMD Patients in Europe and Israel 3 pages 72.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated March 27, 2018, announcing the dosing of patients in a Phase 2b clinical trial for OPT-302 by Opthea Limited. It provides detailed information about the clinical trial progress, study design, regulatory approvals, and company background. There are no financial statements, earnings data, or regulatory certifications present. The document is a corporate announcement about clinical trial progress and company developments rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under a general regulatory announcement or corporate update category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-03-26 English
Opthea Half Year Report and Accounts 22 pages 467.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4D Half-Year Financial Report' and specifies the reporting period as the half-year ended 31 December 2017. It includes detailed financial data such as revenues, losses, net tangible asset backing, and a review of operations. The document contains a Directors' report, Auditor's independence declaration, financial statements, Directors' declaration, and an Independent auditor's review report. The content is comprehensive and covers financial performance, position, operational updates, and clinical trial progress, consistent with a half-year financial report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2018-02-18 English
Appendix 3B 13 pages 154.9KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issuance of new securities, specifically the issuance of fully paid ordinary shares pursuant to the exercise of options. It includes detailed information about the class and number of securities issued, issue price, purpose, and compliance with ASX rules. The document also contains a quotation agreement for the securities to be quoted on the ASX. This type of document is a formal announcement of a capital raising or share issue event, not a full financial report or earnings release. It matches the description of a 'Share Issue/Capital Change' announcement, which covers new share issues and related capital structure changes. The document is lengthy (15,000 characters) and contains substantive details about the share issuance, confirming it is not merely a brief notice or report publication announcement.
2018-01-11 English
Opthea Receives A$2.7m R&D Tax Incentive 3 pages 65.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated January 8, 2018, announcing that Opthea Limited has received a A$2.7 million research and development tax incentive from the Australian Taxation Office (ATO) for R&D costs incurred in the 2017 financial year. The text provides background on the R&D tax incentive program, details about the company's lead molecule OPT-302, and general information about the company and its clinical trials. There are no financial statements, detailed financial performance data, or comprehensive management discussion of results. The document is a corporate announcement about receiving a government tax credit, not a financial report or earnings release. It is not a regulatory filing or certification letter. The document is a company announcement about a financing-related event (receipt of a tax incentive which increases resources for R&D). This fits best under Capital/Financing Update (CAP) as it relates to an update on company financing activities (receipt of a government R&D tax credit). The document length is about 9,569 characters, which is substantive and not a mere brief announcement or report publication notice. Therefore, the classification is CAP with high confidence.
2018-01-07 English
Opthea Corporate Presentation - January 2018 31 pages 2.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Opthea Limited's OPT-302 drug development program, including scientific background, clinical trial design, financial position, market opportunity, and milestones. It contains extensive information on the company's strategy, clinical trials, and financial data but is structured as a presentation rather than a formal regulatory filing or report. There is no indication that this is an official annual or interim report, audit report, earnings release, or regulatory filing. The content is typical of an investor presentation aimed at providing detailed information to investors about the company's product pipeline, clinical progress, and financial status. Therefore, the document best fits the category of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2018-01-07 English
Opthea Initiates OPT-302 Diabetic Macular Edema Trial 6 pages 411.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated January 3, 2018, announcing the initiation of a Phase 1b/2a clinical trial for OPT-302 in diabetic macular edema (DME). It includes detailed information about the clinical trial design, objectives, endpoints, and background on the drug and disease. The document is a public announcement of a clinical trial start, not a financial report or regulatory filing. It does not contain financial statements, earnings data, or management discussion of financial results. It is also not a regulatory filing or certification. The document is a corporate announcement related to clinical development progress, which fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories like earnings release or capital update. The document length is 15,000 characters, which is substantial but the content is clearly an announcement rather than a report or transcript. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-01-02 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.